vs
Side-by-side financial comparison of Astera Labs, Inc. (ALAB) and AVANOS MEDICAL, INC. (AVNS). Click either name above to swap in a different company.
Astera Labs, Inc. is the larger business by last-quarter revenue ($270.6M vs $180.9M, roughly 1.5× AVANOS MEDICAL, INC.). Astera Labs, Inc. runs the higher net margin — 16.6% vs -0.7%, a 17.3% gap on every dollar of revenue. On growth, Astera Labs, Inc. posted the faster year-over-year revenue change (91.8% vs 0.7%). Astera Labs, Inc. produced more free cash flow last quarter ($76.6M vs $21.3M). Over the past eight quarters, Astera Labs, Inc.'s revenue compounded faster (103.6% CAGR vs 4.4%).
Astera Labs, Inc. is an American fabless semiconductor manufacturer and artificial intelligence company. The company specializes in designing high-speed connectivity solutions for data centers and AI infrastructure. The company has been listed on the Nasdaq since March 2024.
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
ALAB vs AVNS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $270.6M | $180.9M |
| Net Profit | $45.0M | $-1.3M |
| Gross Margin | 75.6% | 47.5% |
| Operating Margin | 24.7% | 1.4% |
| Net Margin | 16.6% | -0.7% |
| Revenue YoY | 91.8% | 0.7% |
| Net Profit YoY | 82.0% | 99.7% |
| EPS (diluted) | $0.25 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $270.6M | $180.9M | ||
| Q3 25 | $230.6M | $177.8M | ||
| Q2 25 | $191.9M | $175.0M | ||
| Q1 25 | $159.4M | $167.5M | ||
| Q4 24 | $141.1M | $179.6M | ||
| Q3 24 | $113.1M | $170.4M | ||
| Q2 24 | $76.8M | $171.7M | ||
| Q1 24 | $65.3M | $166.1M |
| Q4 25 | $45.0M | $-1.3M | ||
| Q3 25 | $91.1M | $-1.4M | ||
| Q2 25 | $51.2M | $-76.8M | ||
| Q1 25 | $31.8M | $6.6M | ||
| Q4 24 | $24.7M | $-397.3M | ||
| Q3 24 | $-7.6M | $4.3M | ||
| Q2 24 | $-7.5M | $1.8M | ||
| Q1 24 | $-93.0M | $-900.0K |
| Q4 25 | 75.6% | 47.5% | ||
| Q3 25 | 76.2% | 48.4% | ||
| Q2 25 | 75.8% | 52.6% | ||
| Q1 25 | 74.9% | 53.6% | ||
| Q4 24 | 74.0% | 54.6% | ||
| Q3 24 | 77.7% | 54.5% | ||
| Q2 24 | 77.9% | 55.7% | ||
| Q1 24 | 77.4% | 57.1% |
| Q4 25 | 24.7% | 1.4% | ||
| Q3 25 | 24.0% | 0.1% | ||
| Q2 25 | 20.7% | -42.6% | ||
| Q1 25 | 7.1% | 6.1% | ||
| Q4 24 | 0.1% | -233.0% | ||
| Q3 24 | -7.9% | 7.0% | ||
| Q2 24 | -31.7% | 3.7% | ||
| Q1 24 | -127.1% | 2.4% |
| Q4 25 | 16.6% | -0.7% | ||
| Q3 25 | 39.5% | -0.8% | ||
| Q2 25 | 26.7% | -43.9% | ||
| Q1 25 | 20.0% | 3.9% | ||
| Q4 24 | 17.5% | -221.2% | ||
| Q3 24 | -6.7% | 2.5% | ||
| Q2 24 | -9.8% | 1.0% | ||
| Q1 24 | -142.5% | -0.5% |
| Q4 25 | $0.25 | $-0.02 | ||
| Q3 25 | $0.50 | $-0.03 | ||
| Q2 25 | $0.29 | $-1.66 | ||
| Q1 25 | $0.18 | $0.14 | ||
| Q4 24 | $1.23 | $-8.64 | ||
| Q3 24 | $-0.05 | $0.09 | ||
| Q2 24 | $-0.05 | $0.04 | ||
| Q1 24 | $-1.77 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.6M | $89.8M |
| Total DebtLower is stronger | — | $90.3M |
| Stockholders' EquityBook value | $1.4B | $778.2M |
| Total Assets | $1.5B | $1.1B |
| Debt / EquityLower = less leverage | — | 0.12× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.6M | $89.8M | ||
| Q3 25 | $140.4M | $70.5M | ||
| Q2 25 | $162.3M | $90.3M | ||
| Q1 25 | $86.4M | $97.0M | ||
| Q4 24 | $79.6M | $107.7M | ||
| Q3 24 | $126.1M | $89.0M | ||
| Q2 24 | $421.1M | $92.2M | ||
| Q1 24 | $696.1M | $75.8M |
| Q4 25 | — | $90.3M | ||
| Q3 25 | — | $93.4M | ||
| Q2 25 | — | $95.7M | ||
| Q1 25 | — | $98.0M | ||
| Q4 24 | — | $125.3M | ||
| Q3 24 | — | $152.6M | ||
| Q2 24 | — | $164.9M | ||
| Q1 24 | — | $167.2M |
| Q4 25 | $1.4B | $778.2M | ||
| Q3 25 | $1.3B | $778.0M | ||
| Q2 25 | $1.1B | $776.3M | ||
| Q1 25 | $1.0B | $839.4M | ||
| Q4 24 | $964.8M | $828.5M | ||
| Q3 24 | $889.6M | $1.2B | ||
| Q2 24 | $845.3M | $1.2B | ||
| Q1 24 | $808.8M | $1.2B |
| Q4 25 | $1.5B | $1.1B | ||
| Q3 25 | $1.4B | $1.1B | ||
| Q2 25 | $1.3B | $1.0B | ||
| Q1 25 | $1.1B | $1.1B | ||
| Q4 24 | $1.1B | $1.2B | ||
| Q3 24 | $983.1M | $1.7B | ||
| Q2 24 | $915.5M | $1.7B | ||
| Q1 24 | $864.9M | $1.7B |
| Q4 25 | — | 0.12× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.12× | ||
| Q1 25 | — | 0.12× | ||
| Q4 24 | — | 0.15× | ||
| Q3 24 | — | 0.12× | ||
| Q2 24 | — | 0.13× | ||
| Q1 24 | — | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $95.3M | $28.2M |
| Free Cash FlowOCF − Capex | $76.6M | $21.3M |
| FCF MarginFCF / Revenue | 28.3% | 11.8% |
| Capex IntensityCapex / Revenue | 6.9% | 3.8% |
| Cash ConversionOCF / Net Profit | 2.12× | — |
| TTM Free Cash FlowTrailing 4 quarters | $281.8M | $43.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $95.3M | $28.2M | ||
| Q3 25 | $78.2M | $14.0M | ||
| Q2 25 | $135.4M | $6.8M | ||
| Q1 25 | $10.5M | $25.7M | ||
| Q4 24 | $39.7M | $57.9M | ||
| Q3 24 | $63.5M | $23.0M | ||
| Q2 24 | $29.8M | $27.8M | ||
| Q1 24 | $3.7M | $-8.0M |
| Q4 25 | $76.6M | $21.3M | ||
| Q3 25 | $65.9M | $7.0M | ||
| Q2 25 | $133.3M | $-4.2M | ||
| Q1 25 | $6.0M | $19.0M | ||
| Q4 24 | $24.3M | $53.1M | ||
| Q3 24 | $46.8M | $20.0M | ||
| Q2 24 | $28.5M | $21.9M | ||
| Q1 24 | $228.0K | $-12.1M |
| Q4 25 | 28.3% | 11.8% | ||
| Q3 25 | 28.6% | 3.9% | ||
| Q2 25 | 69.5% | -2.4% | ||
| Q1 25 | 3.7% | 11.3% | ||
| Q4 24 | 17.2% | 29.6% | ||
| Q3 24 | 41.4% | 11.7% | ||
| Q2 24 | 37.1% | 12.8% | ||
| Q1 24 | 0.3% | -7.3% |
| Q4 25 | 6.9% | 3.8% | ||
| Q3 25 | 5.3% | 3.9% | ||
| Q2 25 | 1.1% | 6.3% | ||
| Q1 25 | 2.8% | 4.0% | ||
| Q4 24 | 10.9% | 2.7% | ||
| Q3 24 | 14.8% | 1.8% | ||
| Q2 24 | 1.7% | 3.4% | ||
| Q1 24 | 5.2% | 2.5% |
| Q4 25 | 2.12× | — | ||
| Q3 25 | 0.86× | — | ||
| Q2 25 | 2.64× | — | ||
| Q1 25 | 0.33× | 3.89× | ||
| Q4 24 | 1.61× | — | ||
| Q3 24 | — | 5.35× | ||
| Q2 24 | — | 15.44× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALAB
Segment breakdown not available.
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
